Healthcare, utilities, basic resources and chemicals the best performers; media, travel/leisure, tech and retail lag:
Galderma to present data on its neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid (CHF 158.90, 0.00)
FDA grants orphan drug designation to nemolizumab for systemic sclerosis (CHF 158.90, 0.00)
StreetAccount Sector Summary - Healthcare Post-Market
Galderma Group initiated hold at Deutsche Bank (CHF 163.90, 0.00)
Galderma Group announces the authorization of NEMLUVIO (nemolizumab) for atopic dermatitis and prurigo nodularis in Canada (CHF 164.10, -1.10)
Galderma Group announces new clinical data confirming nemolizumab's rapid onset of action on itch and sleep; data published in the Journal of the European Academy of Dermatology and Venereology (CHF 162.00, 0.00)
Galderma Group announces first patient enrollment for phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CHF 167.80, 0.00)
Insurance, industrials/defense, healthcare the best performers; food/beverage, personal/household goods and autos/arts main laggards:
StreetAccount Macro Headlines:
Powered by FactSet Research Systems Inc.